Author:
Ghosh Wrik,Wickstead Rose,Claxton Lindsay,Kusel Jeanette,Taylor Matthew,Fleetwood Kelly,Pulikottil-Jacob Ruth
Funder
Novartis Pharmaceuticals UK Limited
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference40 articles.
1. Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina (Philadelphia, Pa). 2015;35(8):1489–506.
2. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007–March 2008. Eye (London, England). 2010;24(11):1692–9.
3. Menon G, Walters G. New paradigms in the treatment of wet AMD: the impact of anti-VEGF therapy. Eye. 2009;23(Suppl 1):S1–7.
4. Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96(5):752–6.
5. European Medicines Agency (EMA). Lucentis 10 mg/ml solution for injection. Summary of Product Characteristics. 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf . Accessed 11 Feb 2016.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献